KPL-716
KPL-716-C202
Phase 2 small_molecule completed
Quick answer
KPL-716 for Chronic Idiopathic Urticaria is a Phase 2 program (small_molecule) at Kiniksa Pharmaceuticals International, plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kiniksa Pharmaceuticals International, plc
- Indication
- Chronic Idiopathic Urticaria
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed